002793.SZ
罗欣药业
SZSE · Healthcare · C 制造业 · CN
CNY 4.66
−6.80%Year over year
Reported trailing growth
- Revenue
- -2.8%
- EBITDA
- —
- EBIT
- +69.5%
- EPS
- +70.8%
- Free cash flow
- +1655.6%
- Operating cash flow
- +151.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.1%
- EBITDA
- +87.8%
- EBIT
- +68.7%
- Net income
- +70.1%
- EPS
- +70.0%
- Free cash flow
- -0.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026